# DB-07 (NCT04538742)

> A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04538742
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Breast Cancer
- Interventions: Trastuzumab deruxtecan; Durvalumab; Paclitaxel; Pertuzumab; Tucatinib
- Enrollment: 245
- Primary outcome: Occurrence of adverse events (AEs)- Part 1
- Primary outcome: Occurrence of serious adverse events (SAEs)- Part 1
- Primary outcome: Occurrence of adverse events (AEs)- Part 2
- Primary outcome: Occurrence of serious adverse events (SAEs)- Part 2

## Commentary we found

- X threads: 4
- YouTube: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=db-07-nct04538742